Clinical Manifestations of Pulmonary Mucormycosis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A 21-Case Series Report and Literature Review
Canadian Respiratory Journal · 02.06.2022 · 2022 · 1-10
DOI: 10.1155/2022/1237125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Respiratory Journal, erschienen am 02.06.2022. Verfasst von Jing Bao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Mucormycosis, Mycoses. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project, National Basic Research Program of China.
Abstract (Originalsprache)
Introduction
Mucormycosis is a rare, invasive disease caused by opportunistic pathogens related to the Mucorales order with high fatality rates in immunocompromised hosts, especially in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis and treatment of pulmonary mucormycosis in recipients of allo-HSCT remains challenging.
Purpose
The aim of this study is to summarize and analyze the clinical features of pulmonary mucormycosis in recipients of allo-HSCT to explore further clinical research directions for this rare fungal infection in the particular populations.
Methods
We retrospectively reviewed pulmonary mucormycosis in patients who received allo-HSCT in our hospital from January 2010 to December 2020. A total of 21 patients fulfilled the diagnostic criteria for pulmonary mucormycosis according to the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. Demographic and clinical data, mycological and histopathological records, and treatment and prognosis data were collected. Clinical variables were compared between survivors and nonsurvivors. The survival days of patients with and without graft-versus-host disease (GVHD) and hemoptysis were compared separately.
Results
Most of the recipients of allo-HSCT were male patients with a mean age of 43 years. Acute myeloid leukemia (AML) was the most common primary hematologic malignancy. Extrapulmonary involvement accounted for 28.6%, of the cases, including central nervous system (n = 5) and skin and soft tissue (n = 1). The median time to infection was 96 days after allo-HSCT. Clinical presentations were nonspecific, including fever (76.2%) and cough (85.7%), as well as dyspnea (19.0%), chest pain (38.1%), and hemoptysis (61.9%). Ground-glass infiltrates (95.0%) and nodules/masses (80%) were the most common radiographic patterns on chest CT. The most common pathogen was Rhizopus (63.2%), and breakthrough infection accounted for 90.5%. Fifteen of the patients died within one year, and the median time from diagnosis to death was 47 days.
Conclusion
Mucormycosis is a fatal infection disease. Opportunistic infections in recipients of allo-HSCT are mainly breakthrough infections and may have a seasonal distribution (summer and autumn) and more cases of death in autumn. The marked reversed halo sign can be seen both in the initial stage of infection and after antifungal treatment. In our case series, patients with pulmonary mucormycosis with extrapulmonary involvement 100% died within one year. There are more patients with GVHD before infection and hemoptysis in nonsurvivors than survivors within 100 days. Patients with GVHD before infection and hemoptysis have a shorter survival time than those without.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.
- Department of Respiratory and Critical Care Medicine, Beijing Jishuitan Hospital, Beijing 100035, China.
- Department of Laboratory Medicine, Peking University People's Hospital, Beijing 100044, China.
- Department of Pathology, Peking University People's Hospital, Beijing 100044, China.
ORCID-Profile: Chunyu Liu, Zhancheng Gao
Förderung
- National Science and Technology Major Project
- National Basic Research Program of China
Zitieren
APA
Bao, J., Liu, C., Dong, Y., Xu, Y., Wang, Z., Sun, K., Xi, W., Wang, K., Gong, P., & Gao, Z. (2022). Clinical Manifestations of Pulmonary Mucormycosis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A 21-Case Series Report and Literature Review. Canadian Respiratory Journal, 2022, 1-10. https://doi.org/10.1155/2022/1237125
Vancouver
Bao J, Liu C, Dong Y, Xu Y, Wang Z, Sun K, et al. Clinical Manifestations of Pulmonary Mucormycosis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A 21-Case Series Report and Literature Review. Canadian Respiratory Journal. 2022;2022:1-10. doi:10.1155/2022/1237125
BibTeX
@article{Bao2022,
author = {Bao, Jing and Liu, Chunyu and Dong, Yongxia and Xu, Yu and Wang, Zhanwei and Sun, Kunkun and Xi, Wen and Wang, Keqiang and Gong, Pihua and Gao, Zhancheng},
title = {Clinical Manifestations of Pulmonary Mucormycosis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A 21-Case Series Report and Literature Review},
journal = {Canadian Respiratory Journal},
year = {2022},
volume = {2022},
pages = {1--10},
doi = {10.1155/2022/1237125}
}
EUVIMED